Pregene Biopharma

Executive Summary

Pregene Biopharma, headquartered in Shenzhen, China, is a private biopharmaceutical company established in 2012, specializing in cell and gene therapies for hematological tumors, solid tumors, and autoimmune diseases. The company leverages integrated technology platforms, including nanobody screening, multi-gene editing, and iPSC reprogramming, to develop innovative CAR-T and CAR-NK cell therapies. With a workforce of 50–200 employees, Pregene aims to address unmet medical needs through these cutting-edge cellular medicines.

Upcoming Catalysts (preview)

• Q4 2026Initial Phase 1 data readout for lead CAR-T candidate in hematological tumors60% success
• H1 2027Strategic partnership for CAR-NK platform with a global pharmaceutical company50% success
• H2 2027IND filing for iPSC-derived CAR-NK therapy in autoimmune diseases40% success